鸭胚胎干细胞Avian Vaccine production cell line -BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

鸭胚胎干细胞

Cat No.: NTCC594256

BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

鸭胚干细胞已被多家生物制药公司用于医用及兽用治疗性灭活/减毒病毒及治疗性疫苗生产。多于20类家族的病毒已被证实可在EB66细胞中繁殖扩增，截止目前已有60多种治疗性疫苗正在通过鸭胚胎干细胞细胞进行研发生产，已获批的第一个使用鸭胚胎干细胞细胞生产的疫苗是H5N1流感疫苗。

Group: Bird cell line.

Group: Vaccine production cell line.

Species of origin：

Anas platyrhynchos (Mallard) (Anas boschas)

Breed/subspecies: GL30.

Sex of cell Male

Category Embryonic stem cell

Publications

PubMed=20562528

Olivier S., Jacoby M., Brillon C., Bouletreau S., Mollet T., Nerriere O., Angel A., Danet S., Souttou B.,

Guehenneux F., Gauthier L., Berthome M., Vie H., Beltraminelli N., Mehtali M.

Avian Vaccine production cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic

monoclonal antibodies with enhanced ADCC activity.

MAbs 2:405-415(2010)

PubMed=21502045

Brown S.W., Mehtali M.

The Avian Vaccine production cell line  cell line, application to vaccines, and therapeutic protein production.

PDA J. Pharm. Sci. Technol. 64:419-425(2010)

Description:

The Avian Vaccine production cell line  is a proprietary embryonic stem cell-based technology for the production of a wide variety of human and

veterinary viral and therapeutic vaccines.

It can be used for the manufacturing of inactivated viruses, live attenuated viruses, live vectors, and subunit vaccines.

Today, more than 20 different families of viruses have been shown to efficiently propagate in Avian Vaccine production cell line  and more than 60

human and veterinary Avian Vaccine production cell line based vaccines are currently being developed utilizing the technology in R&D and clinical phases.

The first veterinary vaccine produced in E-66 cells obtained licensure in September 2012 and the H5N1 adjuvanted pandemic

Influenza vaccine produced by the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) in collaboration with GSK is

currently in a New Drug application (NDA)-Phase in Japan.